GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » PS Ratio

EyePoint Pharmaceuticals (STU:PV3B) PS Ratio

: 19.14 (As of Today)
View and export this data going back to 2009. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, EyePoint Pharmaceuticals's share price is €20.90. EyePoint Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €1.09. Hence, EyePoint Pharmaceuticals's PS Ratio for today is 19.14.

The historical rank and industry rank for EyePoint Pharmaceuticals's PS Ratio or its related term are showing as below:

STU:PV3B' s PS Ratio Range Over the Past 10 Years
Min: 1.24   Med: 10   Max: 82.68
Current: 18.11

During the past 13 years, EyePoint Pharmaceuticals's highest PS Ratio was 82.68. The lowest was 1.24. And the median was 10.00.

STU:PV3B's PS Ratio is ranked worse than
66.07% of 999 companies
in the Biotechnology industry
Industry Median: 9.15 vs STU:PV3B: 18.11

EyePoint Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2023 was €0.31. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €1.09.

Warning Sign:

EyePoint Pharmaceuticals Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of EyePoint Pharmaceuticals was 6.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -23.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was 1.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was -1.70% per year.

During the past 13 years, EyePoint Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 351.40% per year. The lowest was -58.10% per year. And the median was 16.80% per year.

Back to Basics: PS Ratio


EyePoint Pharmaceuticals PS Ratio Historical Data

The historical data trend for EyePoint Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.94 2.45 9.53 3.15 19.54

EyePoint Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.15 2.76 8.73 7.10 19.54

Competitive Comparison

For the Biotechnology subindustry, EyePoint Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EyePoint Pharmaceuticals PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's PS Ratio falls into.



EyePoint Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

EyePoint Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=20.90/1.092
=19.14

EyePoint Pharmaceuticals's Share Price of today is €20.90.
EyePoint Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.09.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


EyePoint Pharmaceuticals  (STU:PV3B) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


EyePoint Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


EyePoint Pharmaceuticals (STU:PV3B) Business Description

Traded in Other Exchanges
Address
480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines